Literature DB >> 35856689

Characterization of Functional B-Cell Epitopes at the Amino Terminus of Shigella Invasion Plasmid Antigen B (IpaB).

Siqi Li1, Xinfeng Han1,2, Ipshita Upadhyay1, Weiping Zhang1.   

Abstract

Shigella invasion plasmid antigen B (IpaB) plays an important role in causing shigellosis. While IpaB's protein structure, contribution to disease mechanism, and protective immunity against Shigella infection have been well studied, the significance of individual antigenic domains, especially at the N terminus, has not been systematically characterized. In an attempt to identify IpaB protein functional epitopes and to construct an optimized polyvalent multiepitope fusion antigen (MEFA) immunogen for development of a protein-based cross protective Shigella vaccine, in this study, we in silico identified immunodominant B-cell epitopes from the IpaB N terminus, fused each epitope to carrier protein CsaB (the major subunit of enterotoxigenic Escherichia coli CS4 adhesin) for epitope fusion proteins, immunized mice with each epitope fusion protein, examined IpaB-specific antibody responses, and assessed antibody functional activity against Shigella bacterial invasion. A total of 10 B-cell continuous epitopes were identified from IpaB N terminus, and after being fused to carrier protein CsaB, each epitope induced anti-IpaB IgG responses in the intramuscularly immunized mice. While in vitro antibody invasion inhibition assays demonstrated that antibodies derived from each identified epitope were functional, epitopes 1 (LAKILASTELGDNTIQAA), 2 (HSTSNILIPELKAPKSL), and 4 (QARQQKNLEFSDKI) induced antibodies to inhibit Shigella sonnei and Shigella flexneri invasion at levels similar to those of recombinant IpaB protein, suggesting that these three IpaB epitopes can be used potentially as IpaB-representing antigens to induce protective anti-IpaB antibodies and for construction of an epitope-based polyvalent MEFA protein immunogen for Shigella vaccine development. IMPORTANCE Currently, there are no effective measures for control or prevention of Shigella infection, the most common cause of diarrhea in children 3 to 5 years of age in developing countries. Challenges in developing Shigella vaccines include virulence heterogeneity among species and serotypes. To overcome virulence heterogeneity challenge and to develop a protein-based multivalent Shigella vaccine, we targeted a panel of virulence factors, including invasion plasmid antigens, identified functional antigenic domains or epitopes as representative antigens, and applied the novel epitope- and structure-based vaccinology platform multiepitope fusion antigen (MEFA) to integrate functional antigenic domains or epitopes into a backbone immunogen to produce a polyvalent immunogen for cross protective antibodies. Identification of functional IpaB epitopes from this study enhances our understanding of IpaB immunogenicity and allows us to directly utilize IpaB epitopes for construction of a cross protective polyvalent Shigella immunogen and to accelerate development of a protein-based Shigella vaccine.

Entities:  

Keywords:  Shigella; epitope mapping; invasion plasmid antigen B (IpaB); polyvalent immunogen; vaccine

Mesh:

Substances:

Year:  2022        PMID: 35856689      PMCID: PMC9361828          DOI: 10.1128/aem.00384-22

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   5.005


  47 in total

1.  Co-administration of rIpaB domain of Shigella with rGroEL of S. Typhi enhances the immune responses and protective efficacy against Shigella infection.

Authors:  Sekar Tamil Selvi Chitradevi; Gurpreet Kaur; Sivaramakrishna Uppalapati; Anandprakash Yadav; Dependrapratap Singh; Anju Bansal
Journal:  Cell Mol Immunol       Date:  2015-02-02       Impact factor: 11.530

2.  Structure-function analysis of the Shigella virulence factor IpaB.

Authors:  A Guichon; D Hersh; M R Smith; A Zychlinsky
Journal:  J Bacteriol       Date:  2001-02       Impact factor: 3.490

3.  Travellers' diarrhoea: Impact of TD definition and control group design on study results.

Authors:  Tinja Lääveri; Sari H Pakkanen; Juha Kirveskari; Anu Kantele
Journal:  Travel Med Infect Dis       Date:  2018-02-02       Impact factor: 6.211

4.  Cloning of plasmid DNA sequences involved in invasion of HeLa cells by Shigella flexneri.

Authors:  A T Maurelli; B Baudry; H d'Hauteville; T L Hale; P J Sansonetti
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

5.  Antibody response of monkeys to invasion plasmid antigen D after infection with Shigella spp.

Authors:  E V Oaks; W D Picking; W L Picking
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

6.  Multiepitope Fusion Antigen: MEFA, an Epitope- and Structure-Based Vaccinology Platform for Multivalent Vaccine Development.

Authors:  Siqi Li; Kuo Hao Lee; Weiping Zhang
Journal:  Methods Mol Biol       Date:  2022

7.  Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine.

Authors:  Francisco J Martinez-Becerra; Xiaotong Chen; Nicholas E Dickenson; Shyamal P Choudhari; Kelly Harrison; John D Clements; William D Picking; Lillian L Van De Verg; Richard I Walker; Wendy L Picking
Journal:  Infect Immun       Date:  2013-09-23       Impact factor: 3.441

8.  Extracellular association and cytoplasmic partitioning of the IpaB and IpaC invasins of S. flexneri.

Authors:  R Ménard; P Sansonetti; C Parsot; T Vasselon
Journal:  Cell       Date:  1994-11-04       Impact factor: 41.582

9.  Significance of Enterotoxigenic Escherichia coli (ETEC) Heat-Labile Toxin (LT) Enzymatic Subunit Epitopes in LT Enterotoxicity and Immunogenicity.

Authors:  Jiachen Huang; Qiangde Duan; Weiping Zhang
Journal:  Appl Environ Microbiol       Date:  2018-07-17       Impact factor: 4.792

10.  Vaccination With Mouse Dendritic Cells Loaded With an IpaD-IpaB Fusion Provides Protection Against Shigellosis.

Authors:  Olivia Arizmendi; Prashant Kumar; Qi Zheng; Jason P Stewart; William D Picking; Wendy Picking; Francisco J Martinez-Becerra
Journal:  Front Immunol       Date:  2019-02-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.